1. Evans-Schultes~R, Hofmann A. Tabernanthe Iboga- In: Evans-Schultes R, Hofrnann A, eds- The botany and r.hemistry of hallucinogenes. Sprinyfield: Charles C Thomas Publisher,1980: 235-239.
2 Goutarel R, Gollnhoier 0, Slllans R. Pharmacodynamics and therapeutic apr>lications of iboya and ibogaine. Psychedelic Monoyraphs anrl Essays 1993; 6; 70-111.
3. Lambert M. Sur les proprietes physiologiques de I'ibogaine. Arch Int Pharmacodyn Ther 1902; 10: 101-20. 4. Naranjo C: Psychoterapeutic possibilities of new fantasy-enhancing drugs. Clin Toxicol 1969; 2: 209-24.
5. De Sio F. Notes on the research of ibogaine, used as a doping factor. Medicina Dello Sport 1970; 23~. 362-3 6. Lotsof HS Ibogaine in the treatment of chemical dependence disorders: clinical perspectives. MAPS 1995; 5: 16-27
7. Popik P. Layer RT, Skolnick P. 100 years ot ibogaine: neurochemical and pharmacological ar.tions of a putative anti-addlctive drug. Pharrnacol Rev 1995; 47~. 235-53. 8. Hough LB, Pearl SM, Glick SD. Tissue distribution of ibogaine atter intraperitoneal and subcutaneous administration. Life Sci 1996: 58~. PL119-22.
9. Gallayher CA, liough L8, Keefner SM. Seyed-Mozaffari A, Arr.her S, Glick SD- Ideniliication and quantification ot the indole alkaloid ibogalne in biological samples by ges chromatography-mass spectrometry. Biochem Pharmacol 1995; 49~. 73-9.
10. Pearl SM, Herrick-Davis K, Teitler M, Glick SD. Radioligand-binding study of noribogaine, a likely metabolite ot ibogaine. Brain Res 1995: 675~. 342-4.
11. Obach RS. Pablo J. Mash DC. Cytochrome P4502D6 catalyzes the O-demethyletion ot the psychoactive alkaloid Ibugaine to 12-hydroxyibogamlne. Drug Metab Dispos 1998; 26: 764-8.
12. Staley JK, Ouyang Q. Pablo J, Hearn WL, Flynn DD, Rothrnan RB, Rice KC. Mash DC. Pharmacological screen for actlvities of 12-hydroxyibogamine: o primary metabolite of th© indole alkaloid ibogalne- Psychophannacology 1996; 127: 10-8.
13- Alburges ME. Foltz RL, Moody DE Detormination of ibogaine and 12-hydroxy-ibogamine in plasma by gas chromatography-pos'rtive ion chemical ionization-mass spectrametry. J Anal Toxicol 1995: 19: 381-6.
14. Sershen H, Harsing LG Jr, Hashim A. Lajtha A. Iboqaine reduces amphetamine-induced locomotor stimulation In C57BL/6By mice, but stimulates locomotor activity in rats. Llfe Sci 1992; 51: 1003-11.
15. Pearl SM, Hough LB, Boyd DL, Glick SD. Sex dlfYerences in iboyaine antagonism of rnorphine-induced locornotor activity and in Iboyaine brain levels and rnetabolism. Pharmacol Biochem Behav 1997; 57: 809-15. 16- Sweetnarn PM, Lancaster J, Snowman A, Collins JL, Porschke S. Bauer C, Ferkany J. Receptor binding profile suggests multiple mechanisms of action are responsible for Ibogaine's putative anti-addmtive activity. Psychophnrmacology 7995; 118~. 369-76.
17. Rabin RA, Winier JC.Ibogaine and noribogaine potentiate the inhibltion ot adenylyl cyclase activity by opioid and E-HT receptors. Eur J Pharmacol 1996; 316~. 343-8.
18- Gllck SD, Maisonneuve IM, Pearl SM. Evidence for roles of kappa-opioid and NMDA receptors in the mechanism ot action ot ibogaine. Braln Res 1997; 749~. 340-3. 19- Bowen WD, Vllner BJ, Wllliams W, Beriha CM. Kuehne ME, Jacobson AE. Ibogaine and its congeners are sigrna 2 receptor-selective ligands with moderate affinity. Eur J Pharmacol 1995; 279: R1-3.
20. Trouvin JH, Jacqmin P, Rouch C. Lesne M, Jacquot C. B©nzodiazepino receptors are involved in tabernenthineinduced tremor in vitro and in vivo evidence. Eur J Pharmacol 1987: 140: 303-9.
21. Mash DC, Staley JK, Baumann MH, Rothman RB. Hearn WL. Identification of a primary metabolite of ibogeine that targets serotonin transporters and elevates serotonin- Life Sci 1995~, 57: PL45-50
22. $ershen H, Hashim A, Lajtha A. Effect of ibogaine on serotonergic and dopaminergic inieractions in striatum trom mice and rats. Neurochem Res 1994; 19: 7463-6. 23. Ghen K, Kokate TCi, Donevan SD. Carroll FI, Rogawski MA. Ibogaine block of the NMDA receptor. in vitro and in vivo studies- Neuropharmacology 1996: 35: 423-31. 24. Fryer JD, Lukas RJ. Noncornpetitive tunctional inhibition at diverse, human nicotlnic acotylcholine receptor subtypes by bupropion, phencyclidlne, and ibogaino. J Pharmacol Exp Ther 1999; 28B: 88-92.
25. De Fonseca FR, Navarro M. Role of the limbic systern In dependence on drugs. Ann Med 1998; 30: 397-40526. Wise RA. Neurobiology of addiction. Curr Opin Neurobiol 1996; 6: 243-51.
27. Di Chiara G. Imperato A- Drugs abused by humans preferentialy increase synaptic dopamine concentration in the mesolimbic system of treely mooving rats. Proc Natl Anad Scl USA 1988: 85~. 5274-8.
28. Glick SD, Kuehne ME, Raucci J. Wilson TE, Larson D, Keller RW Jr, Carlson JN. EFfects of iboga alkaloids on morphine and cocalne self-administration In rats~. relationship to tremorigenic effer,ts end to effects on doparnine release in nucleus accumbens and striatum- Brain Res 1994; 657: 14-22.
29. Glick SD. Rossman K. Wany S. Dong N, Keller RW Jr. Local effects of ibogaine on extracellular levels of dopamlne and its metabolites in nucleus accurnbens and striatum: interaciions with D-amphetamine. Brain Ros 1993: 628: 201-8.
30. Reid MS, Hsu K Jr, Souza KH. Broderick PA, Berger
Šptefl L. Nevrobiološki učlnki iboyaina
SP. Neurophannacological characterization of local ibogaine effects on dopamine release. J Neural Transrn 1996:103~. 967-85.
31. French ED, Dillon K, Ali SF- Effects of ibogaine, and cocaine and morphine after ibogaine, on ventral tegmental dopamine neurons. Life Sci 1996; 59~. PL199-205.
32 Maisonneuve IM, Rossman KL, Koller RW Jr, Glick SD. Acute and prolonged effecis of ibogaine on brain dopamine metabolism and inorphine-induced locomotor actlvity in rats- Brain Res 1992; 575~. 69-73.
33. Glick SD, Maisonneuve IS. Mechanlsms of antiaddictive actions ot il>ogaine. Ann N Y Aca<1 Sci 1998; 844: 214-26. 34- Kallvas PW, Nakamura M- Neural systems For behavioral activatlon und rewnrd. Curr Opln Neuroblol 1999; 9: 223-7.
35. Helsley S, Fiorella D, Rabin RA, Winter JC. Effects oi ibogaine on performance in th© 8-ann radial maze-Pharmacol Blochem Behav 1997; 58~. 37-41
36. 0'Hearn E, Molliver ME. Degeneratinn oi Purkinje cells in parasagittal zones o( the cerel>ellar vermis after treatment with ibogaine or harmaline. Neuroscience 1993;55~. 303-10.
37. Maisonneuve IM, Keller RW Jr, Glick SD. Interactions of iboyaine and D-amphetamine: in vivo microdialysis and motor behavior in rats. Brain Res 1992; 579~. 87-92. 38. Maisonneuve IM. Glick SD. Interactions between Ibogaine and cocaine in rats~. in vivo mioro<fialysis and motor behavior. Eur J Pharmacol 1992; 212: 263-6.
39. sershen H, Hashim A, Lajtha A. Gender ditferences in kappa-opioid modulatlon ot cocaine-induned behavior and NMDA-evoked dnpamine release. Brain Res 1998; 801~. 67-71.
40. Maisonneuve IM, Viskerl<E, Mann GL, Bandarage UK, Kuehne ME, Glick SD- Time-depandent interactions between iboga agents and cocalne. Eur J Pharmacol 1997; 336: 123-6.
41. Maisonneuve IM. Keller RW Jr. Glir,k SD. Interactions between ibogaine, a potential anti-addictive agant, and morphine: an in vivo microdialysis study- Eur J Pharmacol 1991; 199: 35-42.
42. Szumlinski KIC, Malsonneuve IM. Glick SD. Ibogaine enhances Ihe expresslon of locomotor sensitization in rats chronically treated with cocaine. Phannacol Biochem Behav 1999; 63: A57-64.
43. Szumlinski KK, Maisonneuve IM, Glick SD- Pretreatment wlth Ihe putatlve antl-addictive drug, iboyaine, increases the potency oi cocaine to ellcit locomotor responding: a study with acute and chronic cocaine-treated rats. Psychopharmacology 1999; 10.5: 227-33.
44. Pearl S'M, Maisonneuve IM, Gliok SD- Prior morphine exposure onhances Ibogeine antagonism oi rnorphine-induced dopamine release in rats. Neurophormacology 1996: 35: 1779-84.
45. Pearl SM, Jphnson DW, Glir,k SD. Prior morphine exposure enhances ibogaine antagonism oi morphine-induced locomotor stimulation- Psychopharrnacology 1995: 121 ~. 470-5.
46- Schneider JA, Sigg EB- Nauropharmacologlc studies on Ibogalne, an indole alkaloid with central stimulating effects. Ann NY Acad Sci 1957: 66: 765-6.
47. Gershon S, Lang WJ- A psychopharmacologlcal study of some indole elkaloids. Arch Int Pharmacodyn Ther 1962: 135: 31-65.
48. Benwell ME. Holtom PE, Moran RJ. Baltour DJ. Nourochemical and behavioural interactions between iboyalne and nicotine in the rat. Br J Pharmacol 199G; 11Z 743-949. Onaivi ES, Ali SF, Chakrabarti A- In vlvo Ibogaino blockade and in vitro PKC action of cocaine. Ann N Y Aca<I Sci 1998; 844: 227-44.
50. Popik P. Facilitation of memory reirieval by the "'antiaddictive" alkaloid, ibogaine. Life Sci 1996: 59~. PL.37985.
51. Kesner RP, Jackson-Smith P, Henry C, Amann K. EIfects of ibogeine on sensory-motor function, activlty, and spatial learniny in rats. Phermacol Biochem Behav 1995: 51-103-9.
52 Aceto MD. Bowman ER, Harris LS- Dependence studies ot new comr>ounds in the rhesus monkey, rat and mouse. NIDA Res Monogr 1990; 95~. 578-631.
53. Bagal AA, Hough LB, Nalwalk JW, Glick SD.Modulation oi rnorphine-induced antinociception by ibogaine and noribodaine. Brain Res 1996; 741: 258-(i2.
54. Bhargava HN, Cao YJ, Zhao GM. Effects of ibogaine and noribogaine on ihe antinocia:pYive action of mu-, deltaand kappa-opioid receptor agonists In mice- Brain Res 1997; 752: 234-8.
55- Cao YJ, Bhargava HN. Effects of Ibogaine un Ihe development of tolerance to antinociceptive action ot mu-, deltaand kappo-opioid rer.eptor agonists in mice. Braln Res 1997:751~. 250-4.
56. Sunder Sharma S. Bhargava HN. Enhancement of morphlne antinociception by iboyaine and noribogalne in morphine-tolerant mice- Pharmacoloyy 1998; 57: 22932.
57. Hajo N. Dupont C, Wepierre J- Eifects of tabernanthine on various cardiovasrular parameters in the rat and dog. J Pharmacol 1981; 12~. 441-53.
58. Harnon G. Castillon A, Gaignault JC, Wor<;el M. Peripheral cardiovescular effects of tabernanthino tartrnfe in anaesthetized rats Arch Int Phannacodyn Ther 1985; 2-76~. 60-72.
59. Blnienda Z, Beaudoin MA. Thorn BT, Prapurna DR, Johnson JH, Fogl© CM. Sllkker W Jr, Ali SE Alteration of electrooncephalogram and monoamine concentrations in rat braln following ibogaine Ireatment. Ann N Y Acad Sci 1998: 844: 26ri-73.